GSK (NYSE:GSK) Upgraded at Berenberg Bank

Berenberg Bank upgraded shares of GSK (NYSE:GSK) from a hold rating to a buy rating in a research report sent to investors on Tuesday, Marketbeat Ratings reports.

A number of other research analysts have also recently commented on the company. Wall Street Zen cut GSK from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Morgan Stanley restated an “underweight” rating on shares of GSK in a research report on Tuesday, August 25th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of GSK in a research note on Thursday, July 30th. Citigroup started coverage on GSK in a research note on Friday, July 24th. They set a “neutral” rating on the stock. Finally, Weiss Ratings lowered GSK from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $56.50.

GSK Price Performance

Shares of GSK opened at $51.06 on Tuesday. GSK has a 1-year low of $39.29 and a 1-year high of $61.69. The stock has a market cap of $103.28 billion, a PE ratio of 15.97, a P/E/G ratio of 2.11 and a beta of 0.35. The firm has a 50-day simple moving average of $51.09 and a two-hundred day simple moving average of $52.51. The company has a debt-to-equity ratio of 0.81, a current ratio of 0.82 and a quick ratio of 0.52.

GSK (NYSE:GSK) last issued its quarterly earnings data on Tuesday, July 28th. The pharmaceutical company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.27 by $0.09. The firm had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.02 billion. GSK had a net margin of 14.56% and a return on equity of 43.23%. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the prior year, the business posted $0.47 EPS. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, analysts forecast that GSK will post 4.81 EPS for the current year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 8th. Investors of record on Friday, August 14th will be issued a $0.4515 dividend. This represents a $1.81 dividend on an annualized basis and a yield of 3.5%. This is a boost from GSK’s previous quarterly dividend of $0.44. The ex-dividend date is Friday, August 14th. GSK’s dividend payout ratio (DPR) is 55.63%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Elyxium Wealth LLC purchased a new position in GSK in the fourth quarter valued at $30,000. Trust Co. of Vermont acquired a new stake in GSK in the second quarter valued at $54,000. Philadelphia Investment Partners LLC acquired a new stake in GSK in the second quarter valued at $70,000. Ancora Advisors LLC purchased a new stake in GSK during the 2nd quarter worth about $71,000. Finally, Bogart Wealth LLC lifted its holdings in GSK by 15.3% during the 1st quarter. Bogart Wealth LLC now owns 1,508 shares of the pharmaceutical company’s stock worth $83,000 after buying an additional 200 shares during the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

About GSK

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company researches, develops and manufactures medicines and vaccines for the prevention and treatment of disease, serving patients and healthcare providers in markets around the world.

GSK focuses on specialty medicines and vaccines in areas including infectious diseases, HIV, respiratory disease, immunology and oncology. Its products include prescription medicines, long-acting treatments and vaccines designed to protect against diseases such as shingles, meningitis, influenza and respiratory syncytial virus (RSV).

The company was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham.